Navigation Links
Keryx Biopharmaceuticals, Inc. Prices Common Stock Offering
Date:5/4/2011

NEW YORK, May 4, 2011 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease ("Keryx" or the "Company"), today announced the pricing of an underwritten registered offering of 7,021,277 shares of its common stock at a price of $4.70 per share.

The aggregate gross proceeds, before commissions and expenses, of the offering will be approximately $33.0 million.  All of the shares are being sold by the Company. The offering is expected to close on May 9, 2011, subject to customary closing conditions.

Stifel Nicolaus Weisel is acting as the sole book-running manager in this offering with Oppenheimer & Co. Inc., Roth Capital Partners, Rodman & Renshaw, LLC, Brean Murray, Carret & Co. and Ladenburg Thalmann & Co. Inc. acting as co-managers, and JMP Securities LLC acting as financial advisor to the Company.  

The shares will be issued pursuant to a shelf registration statement on Form S-3 previously filed with and declared effective by the Securities and Exchange Commission. The Company also will file with the Securities and Exchange Commission a prospectus supplement with respect to the offering.

This announcement shall not constitute an offer to sell or the solicitation of an offer to buy any securities of the Company, nor shall there be any sale of securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Copies of the prospectus supplement and accompanying prospectus may be obtained, when available, by mail from: Stifel, Nicolaus & Company, Incorporated, Equity Syndicate Department, One Montgomery Street, Suite 3700, San Francisco, California 94104, or by phone at (415) 364-2720.

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 studies is being conducted under a Special Protocol Assessment (SPA) agreement with the Food and Drug Administration (FDA). Keryx is also developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex in the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to an SPA agreement with the FDA. Keryx is headquartered in New York City.

KERYX CONTACT:
Lauren Fischer
Director - Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
E-mail: lfischer@keryx.com


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Keryx Biopharmaceuticals Announces Commencement of Phase 3 Program of Ferric Citrate (Zerenex™) in Japan by Partner, Japan Tobacco and Torii Pharmaceutical
2. Keryx Biopharmaceuticals Announces Two Poster Presentations on KRX-0401 (Perifosine) at Upcoming American Association for Cancer Research (AACR) Annual Meeting
3. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2010 Financial Results
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year End 2010 Financial Results on Wednesday, March 9, 2011 at 8:30 a.m. ET
5. Keryx Biopharmaceuticals Announces Oral Presentation of Final Zerenex™ Short-Term Phase 3 Data at the Upcoming National Kidney Foundations 2011 Spring Clinical Meetings
6. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
7. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2010 Financial Results
8. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment In Zerenex Phase 3 Short-Term Study
9. Keryx Biopharmaceuticals to Present at BioCenturys NewsMakers in the Biotech Industry Conference
10. Keryx Biopharmaceuticals to Present at JMP Securities Healthcare Conference
11. Keryx Biopharmaceuticals to Present at the 22nd Annual ROTH OC Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)...  Sorrento Therapeutics, Inc. (NASDAQ: SRNE ... new treatments for cancer and other unmet medical ... announced underwritten public offering of 23,625,084 shares of ... of $2.00 per share, before deducting underwriting discounts ... Sorrento.  The net proceeds to Sorrento from this ...
(Date:4/18/2017)... Ohio , April 18, 2017  Cardinal Health ... Non-GAAP 1 fiscal 2017 earnings per share (EPS) ... and 2019.  This is in conjunction with this morning,s ... Deep Vein Thrombosis and Nutritional Insufficiency businesses. ... from continuing operations will be at the bottom of ...
(Date:4/18/2017)... BLOOMINGTON, Minn. , April 18, 2017 ... ) ("Imprimis"), an ophthalmology-focused pharmaceutical company, and Cameron ... announced the signing of a three-year exclusive sales ... deploy a dedicated sales team to introduce Imprimis, ... primarily focused in 13 states in the U.S. ...
Breaking Medicine Technology:
(Date:4/21/2017)... ... April 21, 2017 , ... Evoke Therapy ... adults, has kicked off its 4th annual Forum for Innovative Treatment Solutions (FITS), ... “Attachment Informed Therapy for Mental Health and Addiction.” , FITS’ 2017 keynote ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... The adage ... Flex House, the next project in the company’s esteemed VISION House demonstration project series. ... use exactly the amount of resources they need to live affordably and abundantly without ...
(Date:4/21/2017)... Arvada, CO (PRWEB) , ... April 21, 2017 ... ... health and performance system, has partnered with O2X , an active lifestyle ... are focused on improving the health of firefighters, police offers, first responders, military ...
(Date:4/21/2017)... CA (PRWEB) , ... April 21, 2017 , ... ... Joseph Health held the much anticipated Regional Primary Care Spring Symposium on April ... in the local medical community, offering physicians and healthcare providers an opportunity to ...
(Date:4/21/2017)... City, UT (PRWEB) , ... April 21, 2017 , ... ... solutions, recently partnered with Advanced Patient Care of Utah (APCUT) and has appointed Rex ... for the next chapter of growth for our agency and our ability to provide ...
Breaking Medicine News(10 mins):